company background image
KTTA logo

Pasithea Therapeutics NasdaqCM:KTTA Stock Report

Last Price

US$7.25

Market Cap

US$7.4m

7D

1.1%

1Y

-3.3%

Updated

28 Mar, 2024

Data

Company Financials

Pasithea Therapeutics Corp.

NasdaqCM:KTTA Stock Report

Market Cap: US$7.4m

KTTA Stock Overview

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases.

KTTA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Pasithea Therapeutics Corp. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Pasithea Therapeutics
Historical stock prices
Current Share PriceUS$7.25
52 Week HighUS$17.40
52 Week LowUS$5.25
Beta0.90
1 Month Change-0.68%
3 Month Change-2.02%
1 Year Change-3.33%
3 Year Changen/a
5 Year Changen/a
Change since IPO-89.82%

Recent News & Updates

Recent updates

We're Not Very Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Rate

Jul 21
We're Not Very Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Rate

Here's Why We're Not At All Concerned With Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Situation

Apr 06
Here's Why We're Not At All Concerned With Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Situation

Shareholder Returns

KTTAUS BiotechsUS Market
7D1.1%0.9%0.2%
1Y-3.3%11.0%28.1%

Return vs Industry: KTTA underperformed the US Biotechs industry which returned 10.3% over the past year.

Return vs Market: KTTA underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is KTTA's price volatile compared to industry and market?
KTTA volatility
KTTA Average Weekly Movement10.9%
Biotechs Industry Average Movement11.7%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: KTTA has not had significant price volatility in the past 3 months.

Volatility Over Time: KTTA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
202015Tiago Marqueshttps://www.pasithea.com

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers.

Pasithea Therapeutics Corp. Fundamentals Summary

How do Pasithea Therapeutics's earnings and revenue compare to its market cap?
KTTA fundamental statistics
Market capUS$7.45m
Earnings (TTM)-US$16.74m
Revenue (TTM)US$486.56k

15.5x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KTTA income statement (TTM)
RevenueUS$486.56k
Cost of RevenueUS$113.20k
Gross ProfitUS$373.36k
Other ExpensesUS$17.11m
Earnings-US$16.74m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-16.07
Gross Margin76.74%
Net Profit Margin-3,440.17%
Debt/Equity Ratio0%

How did KTTA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.